Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy

Vaccine

Volumn 27, Issue 14, 2009, Pages 2065-2069

  De Giovanni, Carla ^a   Nicoletti, Giordano ^b   Landuzzi, Lorena ^b   Croci, Stefania ^a   Palladini, Arianna ^a   Antognoli, Agnese ^a   Murgo, Annalisa ^a   Ianzano, Marianna L ^a   Grosso, Valentina ^a   Stivani, Valeria ^a   Iezzi, Manuela ^c   Musiani, Piero ^c   Nanni, Patrizia ^a   Lollini, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Breast cancer; Tamoxifen; Vaccine

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GAMMA INTERFERON; PLACEBO; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER PREVENTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FOLLOW UP; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CANCER VACCINES; CARCINOMA; CELLS, CULTURED; COMBINED MODALITY THERAPY; FEMALE; GENES, ERBB-2; INTERFERON-GAMMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; SPLEEN; TAMOXIFEN; VACCINATION;

EID: 61549111856     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.113     Document Type: Article

References (24)

1. Singh M.N., Stringfellow H.F., Paraskevaidis E., Martin-Hirsch P.L., and Martin F.L. Tamoxifen: important considerations of a multi-functional compound with organ-specific properties. Cancer Treat Rev 33 April (2) (2007) 91-100
2. Veronesi U., Boyle P., Goldhirsch A., Orecchia R., and Viale G. Breast cancer. Lancet 365 May (9472) (2005) 1727-1741
3. Jordan V.C. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst 99 March (5) (2007) 350-356
4. Czerniecki B.J., Roses R.E., and Koski G.K. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res 67 July (14) (2007) 6531-6534
5. Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 11 Suppl. 1 (2006) 34-41
6. Renard V., and Leach D.R. Perspectives on the development of a therapeutic HER-2 cancer vaccine. Vaccine 25 September (Suppl. 2) (2007) B17-B23
7. Lollini P.L., Cavallo F., Nanni P., and Forni G. Vaccines for tumour prevention. Nat Rev Cancer 6 March (3) (2006) 204-216
8. Emens L.A., Reilly R.T., and Jaffee E.M. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 12 March (1) (2005) 1-17
9. Curigliano G., Spitaleri G., Pietri E., Rescigno M., de Braud F., Cardillo A., et al. Breast cancer vaccines: a clinical reality or fairy tale?. Ann Oncol 17 May (5) (2006) 750-762
10. Mittendorf E.A., Peoples G.E., and Singletary S.E. Breast cancer vaccines: promise for the future or pipe dream?. Cancer 110 October (8) (2007) 1677-1686
11. Nanni P., Landuzzi L., Nicoletti G., De Giovanni C., Rossi I., Croci S., et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol 173 August (4) (2004) 2288-2296
12. Buck M.B., and Knabbe C. TGF-beta signaling in breast cancer. Ann N Y Acad Sci 1089 November (2006) 119-126
13. Nalbandian G., Paharkova-Vatchkova V., Mao A., Nale S., and Kovats S. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol 175 August (4) (2005) 2666-2675
14. Sereda D., and Werth V.P. Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 142 January (1) (2006) 70-72
15. Baral E., Nagy E., Kwok S., McNicol A., Gerrard J., and Berczi I. Suppression of lymphocyte mitogenesis by tamoxifen: studies on protein kinase C, calmodulin and calcium. Neuroimmunomodulation 7 2 (2000) 68-76
16. Ottewell P.D., Coleman R.E., and Holen I. From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies. Breast Cancer Res Treat 96 March (2) (2006) 101-113
17. De Giovanni C., Nicoletti G., Landuzzi L., Astolfi A., Croci S., Comes A., et al. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 64 June (11) (2004) 4001-4009
18. Nanni P., Nicoletti G., De Giovanni C., Landuzzi L., Di Carlo E., Cavallo F., et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194 November (9) (2001) 1195-1205
19. Street S.E., Zerafa N., Iezzi M., Westwood J.A., Stagg J., Musiani P., et al. Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res 67 June (11) (2007) 5454-5460
20. Boggio K., Nicoletti G., Di Carlo E., Cavallo F., Landuzzi L., Melani C., et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188 August (3) (1998) 589-596
21. Nanni P., Nicoletti G., Palladini A., Croci S., Murgo A., Antognoli A., et al. Antimetastatic activity of a preventive cancer vaccine. Cancer Res 67 November (22) (2007) 11037-11044
22. Menard S., Aiello P., Tagliabue E., Rumio C., Lollini P.L., Colnaghi M.I., et al. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res 60 January (2) (2000) 273-275
23. Nanni P., Nicoletti G., De Giovanni C., Landuzzi L., Di Carlo E., Iezzi M., et al. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int J Cancer 105 June (3) (2003) 384-389
24. Sacco M.G., Soldati S., Indraccolo S., Cato E.M., Cattaneo L., Scanziani E., et al. Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer. Gene Ther 10 October (22) (2003) 1903-1909